BioXcel Therapeutics Inc
Clinical trials sponsored by BioXcel Therapeutics Inc, explained in plain language.
Biopharmaceutical company developing therapies for neuropsychiatric and neurological disorders using artificial intelligence.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a dissolving film calm agitated teens? new trial begins Results expected Jul 2027 (estimated)
-
Can a pill rouse the immune system against pancreatic cancer?
Disease control CancelledThis early-phase trial is testing whether an experimental oral drug called BXCL701 can change how the immune system responds to pancreatic cancer. The study will enroll people with untreated, locally advanced or metastatic pancreatic cancer who can undergo tumor biopsies before a…
Early phase 1 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a dissolvable film quiet ICU delirium?
Symptom relief CancelledThis phase 2 trial is testing whether a dissolvable film containing dexmedetomidine (BXCL501) can safely and effectively reduce agitation in adult ICU patients who have delirium. The study will compare four different starting doses of the drug against a placebo to find the best b…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC